更新于：2024-11-01

Mayaro Virus Infection

马亚罗病毒感染

更新于：2024-11-01

基本信息

别名

Infection, Mayaro Virus、Mayaro Virus Infection、Mayaro Virus Infections

+ [1]

简介-

关联

项与马亚罗病毒感染相关的药物

scMAYV-E

靶点-

作用机制

免疫刺激剂

在研机构

The Wistar Institute [+1]

原研机构

The Wistar Institute

在研适应症

马亚罗病毒感染

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期1800-01-20

100 项与马亚罗病毒感染相关的临床结果

登录后查看更多信息

100 项与马亚罗病毒感染相关的转化医学

登录后查看更多信息

0 项与马亚罗病毒感染相关的专利（医药）

登录后查看更多信息

项与马亚罗病毒感染相关的文献（医药）

2024-10-19·Journal of Travel Medicine

Mayaro fever in Brazil from 2014 to 2024

Article

作者: Carvalho, Thialla Andrade ; Martins-Filho, Paulo Ricardo ; dos Santos, Cliomar Alves

The Mayaro virus, an arthropod-borne virus transmitted from mosquitoes to humans, is endemic in Central and South America. From 2014 to 2024, 314 Mayaro fever cases were registered in Brazil, with high-risk clusters in Goiás, Amazonas, and Pará, and an increasing trend of cases in the Amazon region.

2024-10-01·Archives of Microbiology

β-enaminoester derivatives exhibit promising in vitro and in silico antiviral potential against Mayaro virus

Article

作者: Won-Held Rabelo, Vitor ; Palmer Paixão, Izabel Christina Nunes de ; Carlos, Mariana Falcão Lopes Princisval ; Neves Lima, Aurea Echevarria Aznar ; Amorim, Leonardo Dos Santos Corrêa ; da Silva, Carolina Oliveira ; Silva, Luciene Soares ; Barboza, Geicy Kelly Pires ; da Rocha, Natasha Cristina

Mayaro virus (MAYV) is the causative agent of Mayaro fever, which is characterized mainly by acute fever and long-term severe arthralgia, common manifestations of other arbovirus infections, making the correct diagnosis a challenge. Besides, MAYV infections have been reported in South America, especially in Brazil. However, the lack of vaccines or specific antiviral drugs to control these infections makes the search for new antivirals an urgent need. Herein, we evaluated the antiviral potential of synthetic β-enaminoesters derivatives against MAYV replication and their pharmacokinetic and toxicological (ADMET) properties using in vitro and in silico strategies. For this purpose, Vero cells were infected with MAYV at an MOI of 0.1, treated with compounds (50 µM) for 24 h, and virus titers were quantified by plaque reduction assays. Compounds 2b (83.33%) and 2d (77.53%) exhibited the highest activity with inhibition rates of 83.33% and 77.53%, respectively. The most active compounds 2b (EC₅₀ = 18.92 µM; SI > 52.85), and 2d (EC₅₀ = 14.52 µM; SI > 68.87) exhibited higher potency and selectivity than the control drug suramin (EC₅₀ = 38.97 µM; SI > 25.66). Then, we investigated the mechanism of action of the most active compounds. None of the compounds showed virucidal activity, neither inhibited virus adsorption, but compound 2b inhibited virus entry (62.64%). Also, compounds 2b and 2d inhibited some processes involved with the release of new virus particles. Finally, in silico results indicated good ADMET parameters of the most active compounds and reinforced their promising profile as drug candidates against MAYV.

2024-07-01·Heliyon

Development and validation of Mayaro virus with luciferase reporter genes as a tool for antiviral assays

Article

作者: Zhang, Ya-Nan ; Cassani, Natasha Marques ; Jardim, Ana Carolina Gomes ; Costa Oliveira, Ana Laura ; Corbi, Pedro Paulo ; Santos, Igor Andrade ; Marinho, Mikaela Dos Santos ; Dos Santos Pereira, Anna Karla ; Zhang, Bo

Arboviruses are etiological agents in an extensive group of emerging diseases with great clinical relevance in Brazil, due to the wide distribution of their vectors and the favorable environmental conditions. Among them, the Mayaro virus (MAYV) has drawn attention since its emergence as the etiologic agent of Mayaro fever, a highly debilitating disease. To study viral replication and identify new drug candidates, traditional antiviral assays based on viral antigens and/or plaque assays have been demonstrating low throughput, making it difficult to carry out larger-scale assays. Therefore, we developed and characterized two DNA-launched infectious clones reporter viruses based on the MAYV strain BeAr 20290 containing the reporter genes of firefly luciferase (FLuc) and nanoluciferase (NLuc), designated as MAYV-firefly and MAYV-nanoluc, respectively. The viruses replicated efficiently with similar properties to the parental wild-type MAYV, and luminescence expression levels reflected viral replication. Reporter genes were also preserved during passage in cell culture, remaining stably expressed for one round of passage for MAYV-firefly and three rounds for MAYV-nanoluc. Employing the infectious clone, we described the effect of Rimantadine, an FDA-approved Alzheimer's drug, as a repurposing agent for MAYV but with a broad-spectrum activity against Zika virus infection. Additionally, we validated MAYV-nanoluc as a tool for antiviral drug screening using the compound EIDD-2749 (4'-Fluorouridine), which acts as an inhibitor of alphavirus RNA-dependent RNA polymerase.